PROTECT Results
While the trial missed its primary efficacy endpoint, PROTECT:
-
- Demonstrated superior safety
- Showed comparable therapeutic effect to Lovenox®
Results give us confidence in accelerating the development of our solid dosage form of heparin
Supports variety of dosage forms and safety of fixed dose and unmonitored heparin